December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by 858 Therapeutics

News headline image
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
From 858 Therapeutics
Via Business Wire
News headline image
858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, Platinum-Resistant Ovarian Cancer
From 858 Therapeutics
Via Business Wire
News headline image
858 Therapeutics Announces $50 Million Series B Financing
From 858 Therapeutics
Via Business Wire
News headline image
858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting
From 858 Therapeutics
Via Business Wire
News headline image
858 Therapeutics Expands Leadership Team to Support Transition to the Clinic
From 858 Therapeutics
Via Business Wire
News headline image
858 Therapeutics Expands Board of Directors and Leadership Team
From 858 Therapeutics
Via Business Wire
News headline image
858 Therapeutics Launches with Proven Team and $60 Million Series A Financing
From 858 Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.